Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcgamma receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
Reinheit:
>97.0%
CAS Nummer:
[1858168-59-8]
Target-Kategorie:
PD-1/PD-L1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten